The Latest Breaking News from Avid Bioservices

Avid Bioservices Inc (NASDAQ:CDMO) reported Q4 FY22 sales of $31.2 million, up 13% Y/Y, beating the consensus of $28.96 million. The growth is attributed to an increase in the scope of in-process and completed manufacturing runs and process development revenues. The company signed multiple new project orders during Q4 totaling approximately $44…

Avid Bioservices (NASDAQ:CDMO) is set to give its latest quarterly earnings report on Wednesday, 2022-06-29. Here's what investors need to know before the announcement. Analysts estimate that Avid Bioservices will report an earnings per share (EPS) of $0.01.